Back to results
US 9,006,271 B2Granted
5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as NK1 receptor antagonists
AssigneeNeRRe Therapeutics Limited
InventorsGiuseppe Alvaro, Agostino Marasco
Life of this patent
Estimating the term…
Abstract
The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C1-4 alkyl useful in the treatment of diseases and conditions for which antagonism of NK1 receptor is beneficial.
Claims13
A method for treatment of an inflammatory disease in mammals, which comprises administering to a sufferer a therapeutically effective amount of a compound of formula (I)
- wherein R is C1-4 alkyl, or a pharmaceutical acceptable salt thereof.
Dependencies are inferred from the claim text.